Admission: GENinCode plc
GENinCode plc (GENinCode) is engaged in the risk assessment, prediction and prevention of cardiovascular disease (CVD). Which is the leading cause of death worldwide, accounting for approximately 18 million deaths annually.
GENinCode's products and technology have been developed since 2008 and clinically tested on over 75,000 patients with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management.
The company was incorporated in September 2018 following the acquisition of the assets and know-how of the Ferrer inCode and Gendiag.exe businesses, including the current product portfolio, Cardio inCode®, LiPID inCode®, SuDD inCode® and Thrombo inCode®. It then became a part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharma and healthcare company.
The group's operations are predominantly based in the UK, Europe and, following regulatory clearance, the United States.
Crowe's role and team
Crowe acted as reporting accountant on the transaction. The capital markets team was led by Mitesh Patelia, George Lawford and Ed Beddows.
Client quote
"We valued the assistance of the Capital Markets team at Crowe in helping us with our successful IPO. They were a pleasure to work with and we appreciated their professional and efficient approach. This deal marks an important step to accelerate growth, particularly the roll-out into the United States.”
Matthew Walls, Chief Executive Officer, GENinCode plc
